Linked Life Data

2140243

Source:http://linkedlifedata.com/resource/pubmed/id/2140243

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1990-6-20
pubmed:abstractText
Thirty Egyptian males, 8-31 years of age, with active Schistosoma mansoni infection and negative serologic tests for hepatitis B markers, were vaccinated with a recombinant hepatitis B vaccine (Merck's Recombivax). The vaccine was given intramuscularly in the deltoid region in three 10 micrograms doses at 0, 1, and 6 months. All patients were treated with praziquantel 2 months after the first vaccination. Sera were collected every 2 months for 12 months and tested for anti-HBs using a quantitative ELISA technique. There were no side reactions except for mild local soreness at the injection site in 3 patients. At 12 months, all subjects seroconverted (antibody levels greater than 10 mIU/mL); 24 patients (80%) developed antibody levels greater than 1,000 mIU/mL. As with a plasma-derived vaccine, antibody levels were negatively correlated with increasing spleen size. A recombinant hepatitis B vaccine was safe and immunogenic when given to patients with schistosomiasis mansoni.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0002-9637
pubmed:author
pubmed:issnType
Print
pubmed:volume
42
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
449-52
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Safety and immunogenicity of a recombinant hepatitis B vaccine in patients infected with Schistosoma mansoni.
pubmed:affiliation
Clinical Investigation Division, U.S. Naval Medical Research Unit No. 3 (NAMRU-3), Cairo, Egypt.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S.